Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Hruby Dennis E
  2. Issuer Name and Ticker or Trading Symbol
SIGA TECHNOLOGIES INC [SIGA]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
VP & Chief Scientific Officer
(Last)
(First)
(Middle)
C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET
3. Date of Earliest Transaction (Month/Day/Year)
09/11/2018
(Street)

NEW YORK, NY 10065
4. If Amendment, Date Original Filed(Month/Day/Year)
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $.0001 per share 09/11/2018   M   18,174 (1) (2) A $ 3.53 226,314 D  
Common Stock, par value $.0001 per share 09/11/2018   F   8,853 (1) (2) D $ 7.16 217,461 D  
Common Stock, par value $.0001 per share 09/11/2018   M   50,000 (4) A $ 4.7 267,461 D  
Common Stock, par value $.0001 per share 09/11/2018   F   32,821 (4) D $ 7.16 234,640 D  
Common Stock, par value $.0001 per share 09/11/2018   M   25,000 (6) A $ 0 259,640 D  
Common Stock, par value $.0001 per share 09/11/2018   F   12,175 (6) D $ 7.16 247,465 D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock-Settled Stock Appreciation Rights $ 3.53 09/11/2018   M     37,500   (3) 02/02/2022 Common Stock, par value $.0001 per share 37,500 $ 0 0 D  
Stock Option (Right to buy) $ 4.7 09/11/2018   M     50,000   (5) 03/05/2019 Common Stock, par value $.0001 per share 50,000 $ 0 0 D  
Restricted Stock Units (7) 09/11/2018   M     25,000   (7)   (7) Common Stock, par value $.0001 per share 25,000 $ 0 0 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Hruby Dennis E
C/O SIGA TECHNOLOGIES, INC.
31 EAST 62ND STREET
NEW YORK, NY 10065
      VP & Chief Scientific Officer  

Signatures

 /s/ Dennis E. Hruby   09/13/2018
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) This Form 4 reports the exercise of 37,500 stock-settled appreciation rights ("SSARs") for shares of common stock of SIGA Technologies, Inc. (the "Issuer") granted on February 12, 2012 and the related surrender to the Issuer of 8,853 shares of common stock of the Issuer by the Reporting Person in order to satisfy certain tax withholding obligations of the Issuer associated with the exercise of SSARs and the consequent issuance of common stock of the Issuer. No shares of common stock of the Issuer were sold by the Reporting Person in a market transaction.
(2) Each SSAR consists of the right to receive an amount, in common stock, equal to the excess of the fair market value of a share of common stock of the Issuer (subject to a cap on the fair market value at $7.00 per share) on the date of exercise over the exercise price of such SSAR. The number of shares of common stock issued was determined by dividing the total of all exercised SSARs by the fair market value of a share of common stock of the Issuer on the date of exercise.
(3) The SSARs vested in equal yearly installments over a period of three (3) years, with the first 1/3 of such SSARs vesting on February 2, 2013, the second 1/3 of such SSARs vesting on February 2, 2014, and the remaining 1/3 of such SSARs vesting on February 2, 2015.
(4) This Form 4 reports the exercise of options for 50,000 shares of common stock of the Issuer granted on March 5, 2009 and the related surrender to the Issuer of 32,821 shares of common stock of the Issuer by the Reporting Person in order to effect the option exercise. No shares of common stock of the Issuer were sold by the Reporting Person in a market transaction.
(5) The options vested in equal yearly installments over a period of three (3) years, with the first 1/3 of such options vesting on March 5, 2010, the second 1/3 of such options vesting on March 5, 2011, and the remaining 1/3 of such options vesting on March 5, 2012.
(6) This Form 4 reports the vesting of 25,000 restricted stock units ("RSUs") granted on June 8, 2017 and the consequent issuance of common stock of the Issuer, and the related surrender to the Issuer of 12,175 shares of common stock of the Issuer by the Reporting Person in order to satisfy certain tax withholding obligations of the Issuer associated with the vesting of RSUs and the consequent issuance of common stock of the Issuer. No shares of common stock of the Issuer were sold by the Reporting Person in a market transaction. Each RSU converts into one share of common stock of the Issuer on a one for one basis.
(7) The RSUs vested upon the U.S. Food & Drug Administration's final approval of TPOXX for the treatment of orthopoxvirus infections.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.